• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $52 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-24 Mln

Cellectar Biosciences Inc. (CLRB) Share Price

$4.20

As on 01-Mar-2024 16:12 EST

up-down-arrow $0.287.14%

  • Prev Close info

    $3.92

  • Day's Openinfo

    $4.00

  • Today's Highinfo

    $4.20

  • Today's Lowinfo

    $3.93

  • Today's Volumeinfo

    805,823

  • 52 Week rangeinfo

    $1.30 - 4.38

Please wait...

Cellectar Biosciences Inc. (CLRB) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cellectar Biosciences (CLRB)
51.62 7.42 70.04 169.23 -39.11 -27.03 -52.90
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Cellectar Biosciences (CLRB)
61.99 -74.09 -68.27 -7.56 45.16 -88.55 12.30
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Cellectar Biosciences Inc. (CLRB) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Cellectar Biosciences Inc. (CLRB)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Cellectar Biosciences Inc. (CLRB)

        President, CEO & Director

        Mr. James V. Caruso

        VP, CFO & Secretary

        Mr. Chad J. Kolean CPA

        Headquarters

        Florham Park, NJ

        FAQs for Cellectar Biosciences Inc. (CLRB)

        The total asset value of Cellectar Biosciences Inc. (CLRB) stood at $ 38 Mln as on 30-Sep-23

        The share price of Cellectar Biosciences Inc. (CLRB) is $4.20 (NASDAQ) as of 01-Mar-2024 16:12 EST. Cellectar Biosciences Inc. (CLRB) has given a return of -39.11% in the last 3 years.

        Cellectar Biosciences Inc. (CLRB) has a market capitalisation of $ 52 Mln as on 01-Mar-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Cellectar Biosciences Inc. (CLRB) is 2.67 times as on 01-Mar-2024, a -0.1% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Cellectar Biosciences Inc. (CLRB) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Cellectar Biosciences Inc. (CLRB) and enter the required number of quantities and click on buy to purchase the shares of Cellectar Biosciences Inc. (CLRB).

        Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

        The CEO & director of Mr. James V. Caruso. is Cellectar Biosciences Inc. (CLRB), and CFO & Sr. VP is Mr. Chad J. Kolean CPA.

        The promoters of Cellectar Biosciences Inc. (CLRB) have pledged 0% of the total equity as on Dec-23.

        Cellectar Biosciences Inc. (CLRB) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Cellectar Biosciences Inc. (CLRB) was $-24 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $51.61 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-23.66 Mln
        • Cash date-information $18.99 Mln
        • Total Debt info $0.57 Mln
        • Insider's Holding 3.78%
        • Liquidity liquidity High
        • 52 Week range week-range $1.30 - 4.38
        • Shares outstanding share-outstanding 12,288,300
        • 10 Years Aggregate:

          CFO: $-151.41 Mln

          EBITDA: $-139.66 Mln

          Net Profit: $-165.54 Mln

        About The Company

        • IPO Date 10-Nov-2005
        • President, CEO & Director Mr. James V. Caruso
        • VP, CFO & Secretary Mr. Chad J. Kolean CPA
        • Listing key-listing NASDAQ: CLRB
        • Country United States
        • Headquarters headquarters Florham Park, NJ
        • Website website https://www.cellectar.com
        • Business

          Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131),...  which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.  Read more

        share-fund-plan-icon